Novartis has unilaterally terminated its manufacturing lease with Chinese CDMO Porton Pharma Solutions, seeking approximately $64 million in damages.

Bristol Myers Squibb and Jiangsu Hengrui Medicine have announced the largest strategic collaboration between a Western pharma company and a Chinese drug developer, valued at up to $15.2 billion.